Affordable Access

Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies.

Authors
Type
Published Article
Journal
American Journal of Physiology - Renal Physiology
1931-857X
Publisher
American Physiological Society
Publication Date
Volume
283
Issue
6
Identifiers
PMID: 12426233
Source
Medline
License
Unknown

Abstract

The incidence of progressive nephropathies and, consequently, the population suffering from end-stage renal disease have increased steadily in recent years, posing an ever-growing cost, in both human and financial terms, to society. There is mounting evidence that, in both immune-mediated and nonimmune-mediated chronic nephropathies, renal inflammatory events are key to the propagation and perpetuation of renal injury. Mycophenolate mofetil (MMF) is an antilymphocyte agent recently introduced in clinical practice for the prevention of allograft rejection. The present review discusses clinical and experimental evidence that the anti-inflammatory action of MMF can be advantageously used to arrest immune- and nonimmune-mediated progressive injury of native kidneys as well.

Statistics

Seen <100 times